News Archive

2020

May

Media Release / May 06, 2020

Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14

Read More

April

Media Release / Apr 03, 2020

Novartis and the Novartis US Foundation establish USD 5 million US COVID-19 Community Response Fund

Read More

March

Media Release / Mar 28, 2020

Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Read More
Media Release / Mar 28, 2020

Novartis new analysis further showed durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Read More
Media Release / Mar 18, 2020

Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy

Read More
Media Release / Mar 18, 2020

Novartis Pharmaceuticals Corporation corrective action for certain blister packages of SANDIMMUNE® and NEORAL® 100-mg soft gelatin capsules in the US due to failure to meet child-resistant packaging requirements

Read More

February

Media Release / Feb 11, 2020

Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review

Read More

January

Media Release / Jan 16, 2020

Public-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People

Read More
2019

December

Media Release / Dec 11, 2019

Novartis announces FDA filing acceptance of Xolair® (omalizumab) for treatment of nasal polyps

Read More
Media Release / Dec 09, 2019

Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting

Read More

Related Links